30 results about "Sacroiliac joint inflammation" patented technology

The invention discloses a siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and an application of the siRNA. The invention discloses a chemically-modified dual-chain siRNA molecule, and particularly relates to a dual-chain siRNA molecule which is formed by chemically modifying and supplementing (as shown in (1) to (13)) at least one chain in the siRNA molecule indicated by A. The siRNA can be used as a treatment drug for arthritis and relevant inflammations, and the siRNA and preparations of the siRNA can be locally injected through a bone joint cavity to inhibit the inflammation factor expression so as to realize the treatment for the arthritis.

The invention discloses an siRNA (small interfering ribonucleic acid) composition inhibiting an ADAMTS-5 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs-5) gene and an ADAM17 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs 17) gene and an application of the siRNA composition. The invention discloses the chemically modified double-chain siRNA molecular composition which comprises at least one of double-chain siRNA molecules as shown as (1) and at least one double-chain siRNA molecules as shown as (2). The siRNA composition can serve as a treatment medicine of arthritis and relevant inflammation, and the siRNA composition and a preparation of the siRNA composition can be injected locally through a bone articular cavity to inhibit inflammatory factor expression to achieve treatment of the joint inflammation.

The invention discloses siRNA for inhibiting a gene ADAMTS-5 and application of the siRNA. The invention discloses a chemically modified double-chain siRNA molecule which is formed in the way that any chemical modification from (1) to (13) in the Specification is performed on at least one of the chains in the siRNA molecule in A (in the Specification), and the complementation is performed. The siRNA disclosed by the invention can be used as a medicine for treating arthritis and related inflammations, and the siRNA and a preparation thereof can be injected into local parts of bone joint cavities to inhibit the expression of inflammatory factors and further realize treatment of joint inflammation.

The invention discloses a long non-coding RNA (lncRNA) and application thereof in diagnosis / treatment of rheumatoid arthritis (RA). The lncRNA is lncRNA RP1-90J20.8. The invention relates to application of the lncRNA in evaluation of the severity of RA joint inflammation and joint damage and target drug therapy. A reagent for detecting the lncRNA RP1-90J20.8 can assist in RA diagnosis, evaluation and joint erosion damage judgment; and a target silent lncRNA RP1-90J20.8 gene can be used for inhibiting joint damage and assisting in treatment of RA. According to the invention, the biological function and clinical significance of the lncRNA RP1-90J20.8 in RA are clarified; a sufficient theoretical basis is provided for taking the lncRNA RP1-90J20.8 as a marker for auxiliary diagnosis of RA and prediction of RA prognosis and a new therapeutic target; and the lncRNA RP1-90J20.8 has great significance and application prospects in development of auxiliary diagnosis, prognosis evaluation and therapeutic drugs for RA.

The invention discloses an application of cnidium lactone as an [alpha]36 estrogen receptor activator, in particular an application of the cnidium lactone as the [alpha]36 estrogen receptor activator in preparing medicines or health care foods for preventing and treating osteoporosis, premature ovarian failure, climacteric syndrome, irregular menstruation, infertility, degenerative disc disease, bone joint inflammatory and immunological diseases, cardiovascular disease, alzheimer disease or bone metastases from cancer. The invention also discloses the [alpha]36 estrogen receptor activator, and cnidium lactone serves as an active ingredient of the [alpha]36 estrogen receptor activator at a concentration of 0.01-10 [mu]M.

The invention discloses a biological agent for preventing and relieving joint sub-health and a preparation method thereof, and belongs to the technical field of biological agents. The biological agent of the present invention contains a plurality of bioactive components and a plurality of active ingredients of Chinese herbs. The bioactive components comprise S-adenosylmethionine, sodium hyaluronate, sodium chondroitin sulfate, vitrin and acetyl glucosamine, can prevent decomposition of proteoglycan by enzyme, provide exogenous hyaluronic acid for human joints, activate synthesis of mucopolysaccharide in the body, and promote synthesis of hyaluronic acid and collagen and cartilage regeneration. The bioactive components can improve content of hyaluronic acid in the body, reduce cartilage loss and maintain morphology of cartilage and synovial fluid. The active ingredients of Chinese herbs comprise fructus liquidambaris extract, herba lycopodii extract, fructus morinda citrifolia and ginger root extract, and have the effects of relaxing tendons and activating collaterals, promoting blood circulation to remove blood stasis, improving local microcirculation and relieving pain. According to the biological agent, Chinese medicines and western medicines are combined to fundamentally prevent and relieve joint inflammation.

The invention relates to a compound preparation for treating rheumatoid arthritis. The compound preparation is prepared from the following crude drugs in parts by weight: 5 to 12 parts of fried fructus arctii, 4 to 11 parts of bombyx batryticatus, 8 to 15 parts of radix notoginseng, 4 to 12 parts of radix angelicae pubescentis, 3 to 9 parts of radix gentianae macrophyllae, and 4 to 12 parts of rhizoma pinelliae. The animal experiment shows that the compound preparation can reduce an inflammatory infiltration area, bony defects and articular cartilage defects of TNF-Tg rheumatoid arthritis mice, can promote lymphatic return and can alleviate ankle joint inflammatory injury. The traditional Chinese medicine compound preparation can improve the rheumatoid arthritis symptom, and can avoid the inconvenience caused by the temporary decoction of the traditional Chinese herbal decoction before the administration and the likeliness in mildew; and in addition, the invention also provides a preparation method of the compound preparation.

The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to decrease joint instability, increase joint stability, decrease joint stiffness, improve joint function, improve joint health, improve balanced movement and improve skeletal joint stability during muscle movement. HMB is administered to increase muscle strength and / or muscle mass in a side of the body contralateral to joint inflammation, joint damage, and / or joint injury.

The invention relates to an application of LCA (9, 9'-O-bi-(E)-feruloylated-meso-5, 5'-dimethoxy secoisolariciresinol) in preparation of drug for treating arthritis or cartilago articularis and bone destruction. By using a cell heat transfer technology, the compound LCA can be combined with MEK1 protein and cathepsinK protein in cells, animal tests verify that the LCA can improve the symptoms of a rat with rheumatoid arthritis and the research results show that LCA has a double target effects of simultaneously inhibiting immune inflammation and preventing and treating bone destruction and has a board application prospect in clinical treatment of diseases such as rheumatoid arthritis, osteoarthritis, osteoporosis and the like.

The invention discloses a composite hyaluronic acid composition for preventing and relieving joint diseases, and belongs to the technical field of osteoarthritis health care products. Comprising hyaluronic acid, Anbenefit milk polypeptide, collagen peptide, chitosan oligosaccharide, chondroitin sulfate, glucosamine, vitamin D3, calcium carbonate, donkey-hide gelatin, ginseng peptide powder, licorice powder, curcumin, a plant extract, magnesium sulfate, manganese sulfate and zinc sulfate. The composite hyaluronic acid composition disclosed by the invention can be used for solving arthralgia, solving the problem of joint inflammation from the perspective of tonifying both inside and outside, promoting absorption of nutrient substances by joints, supplementing precursor substances of articular cartilage and synovial fluid, improving the overall health level, stimulating the repair capability of a human body, promoting absorption of nutrients and reducing pain.

The invention provides an application of pericarpium citri reticulatae essential oil to preparation of products for preventing or treating arthritis. Research results show that a pericarpium citri reticulatae essential oil component can relieve CFA-induced rheumatoid arthritis of rats and can effectively relieve joint tissue damage caused by CFA; and the pericarpium citri reticulatae essential oilcan inhibit the lesion degree of arthritis by inhibiting activity expression of tumor necrosis factors TNF-alpha and COX-2, and control the joint arthritis reaction, so that the pain of a patient caused by the arthritis is relieved to the greatest extent, and a new choice is provided for developing novel anti-arthritis medicines.

The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to decrease joint instability, increase joint stability,decrease joint stiffness, improve joint function, improve joint health, improve balanced movement and improve skeletal joint stability during muscle movement. HMB is administered to increase muscle strength and / or muscle mass in a side of the body contralateral to joint inflammation, joint damage, and / or joint injury.

The invention belongs to the technical field of plaster and its preparation. The invention discloses an external plaster for treating joint pain and arthritis and a preparation method thereof. The plaster is composed of capsicum, menthol, borneol, rubber, lanolin, zinc oxide, rosin, beeswax, coating agent and gasoline and other raw materials, and its preparation method consists of steps such as material preparation, pharmacy, rubber mixing, coating, beating, glue coating, drying and post-treatment. (1) The external plaster used for the treatment of joint pain and arthritis in the present invention has the functions of dispelling wind and cold, relaxing tendons and activating collaterals, reducing swelling and relieving pain, etc., and can be used for joint pain, backache, sprain, bruise and chronic arthritis and the treatment of diseases such as non-ulcerated chilblains; at the same time, it has good air permeability, has a good sustained-release effect, and the drug has a long onset time; the preparation method of the external plaster for treating joint pain and arthritis in the present invention is simple, Easy to implement on existing equipment.

The invention discloses an siRNA (small interfering ribonucleic acid) composition inhibiting an ADAMTS-5 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs-5) gene and an ADAM17 (a disintegrin-like and metalloproteinase with thrombospondin type 1motifs 17) gene and an application of the siRNA composition. The invention discloses the chemically modified double-chain siRNA molecular composition which comprises at least one of double-chain siRNA molecules as shown as (1) and at least one double-chain siRNA molecules as shown as (2). The siRNA composition can serve as a treatment medicine of arthritis and relevant inflammation, and the siRNA composition and a preparation of the siRNA composition can be injected locally through a bone articular cavity to inhibit inflammatory factor expression to achieve treatment of the joint inflammation.

Femoral head necrosis is a pathologic evolution process and firstly happens in a bearing area of a femoral head, under the action of stress, a necrosis bone trabecula structure can be damaged, that is, microscopy bone fracture, the following reparative process is not complete, and the process of damage-repairing is continued, so that the femoral head structure is changed, the femoral head is collapsed and deformed, and joint inflammation can be caused. Pain, joint action obstacle and loaded walking dysfunction can be caused by femoral head. The medicine is prepared from medicines including silkworm excrement, herba lycopi, kadsura pepper stems, gadfly, homalomena occulta, leech, erythrina indica lam, philippine flemingia roots, agkistrodon, kadsura coccinea, tiger-bone, folium photiniae, cortex acanthopanacis, turtle shells, taxillus sutchuenensis, morinda officinalis, mulberry twig, epimedium brevicornu, paniculate swallowwort roots, teasel roots, Chinese starjasmine stems, English walnut seeds, pawpaw, cistanche, eupatorium, atractylodes macrocephala, rhizoma atractylodis, hyacinth beans, inula flower, caulis spatholobi, pig bile, leonurus, rhizoma sparganii, salvia miltiorrhiza and polygonum cuspidatum. Due to the effects of the combined medicines, a synergistic effect can be achieved, and thus femoral head necrosis can be effectively treated.

A compound as represented by formula (I), and optical isomers, solvates, pharmaceutically-acceptable salts, or prodrugs thereof. The present invention has urate transporter 1 (URAT1) inhibitory activity, can be used for treatment of gout and hyperuricemia, and can also be used for treatment of diseases related to abnormal URAT1 activity, such as recurrent gout attacks, gouty arthritis, hypertension, cardiovascular diseases, coronary heart disease, Lesch-Nyhan syndrome, Kearns-Sayre syndrome, kidney diseases, kidney stones, kidney failure, joint inflammations, arthritis, urolithiasis, lead poisoning, hyperparathyroidism, psoriasis, sarcoidosis, or hypoxanthine-guanine phosphoribosyltransferase deficiency. (I)

The invention relates to betulinic acid derivatives containing pyrazole and a preparation method and application of the betulinic acid derivatives, in particular to compounds with the structure shown in the general formula I. Definitions of all groups are shown in the specification. A rat arthritis model is induced through sodium iodoacetate, and the change of the degree of arthralgia is observed; an in-vitro induced differentiation system is adopted, and the osteoclast differentiation and inflammatory factor generation level of the osteoclast precursor is observed. Results show that the compound adopted by the invention has inhibitory activity on osteoclast differentiation and inflammatory factor generation, has a good treatment effect on osteoarthritis and joint inflammation diseases with bone destruction, bone erosion and synovitis as pathological characteristics, and has an ideal clinical application prospect.

The invention relates to an application of LCA (9, 9'-O-bi-(E)-feruloylated-meso-5, 5'-dimethoxy secoisolariciresinol) in preparation of drug for treating arthritis or cartilago articularis and bone destruction. By using a cell heat transfer technology, the compound LCA can be combined with MEK1 protein and cathepsinK protein in cells, animal tests verify that the LCA can improve the symptoms of a rat with rheumatoid arthritis and the research results show that LCA has a double target effects of simultaneously inhibiting immune inflammation and preventing and treating bone destruction and has a board application prospect in clinical treatment of diseases such as rheumatoid arthritis, osteoarthritis, osteoporosis and the like.

The invention is a "preparation method and application of OPG-HSP70 fusion protein", which belongs to the field of biomedical new technology. The invention provides an osteoprotegerin-heat shock protein 70 (OPG-HSP70) fusion protein drug. The drug targets synovitis, the most important pathological feature of rheumatoid arthritis (RA), accompanied by destruction of cartilage and bone. Through osteoprotegerin (OPG) as a decoy receptor, it can interact with cells expressed by osteoblasts and other cells. Receptor Activator of Nuclear Factor κB Ligand (RANKL) binds, blocks the binding of RANKL to RANK expressed by osteoclasts, thereby inhibiting bone resorption involving osteoclasts; uses the protective polypeptide fragment of heat shock protein (HSP) to inhibit joint inflammation. The invention includes the DNA sequence encoding the fusion protein; the method of producing the fusion protein through recombinant technology; and the biological activity of the fusion protein, etc.

The invention relates to the technical field of medicine, in particular to application of artesunate in treating rheumatoid arthritis model rats. The invention discloses a possible molecular mechanism of artesunate for relieving joint inflammation of a rheumatoid arthritis model rat, and discovers that artesunate can effectively relieve joint swelling and arthritis index of the model rat and improve osteoporosis. The artesunate has the advantages of safety, low price, small side effect and the like, is expected to overcome the problems of poor clinical curative effect, high price, multiple complications and the like of the existing medicine for treating rheumatoid arthritis, and becomes a brand new medicine for treating systemic lupus erythematosus.

The invention relates to a nucleic acid molecule for coding interleukin-1 receptor antagonist protein, a transgenic expression cassette containing the nucleic acid molecule, a gene delivery system containing the transgenic expression cassette and application of the gene delivery system. The transgene expression cassette and the gene delivery system can be used for treating various diseases, including malignant tumors and inflammatory diseases, such as joint inflammation, especially osteoarthritis, which can be improved by blocking an IL-1 signal channel.

The present invention relates to an extract obtained from or obtainable from Rubus idaeus, a composition comprising an extract obtained from or obtainable from Rubus idaeus, processes for providing such an extract, and methods and uses relating to such extracts. In particular, the present invention relates to an extract or composition for use in treating or preventing inflammation, such as arthritis and joint inflammation.

The invention relates to the technical field of medicines, and discloses an application of menthone to preparation of a medicine for treating rheumatoid arthritis. A collagen-induced rheumatoid arthritis mouse model (CIA) proves that the menthone can effectively relieve the rheumatoid arthritis symptom by down-regulating the inflammatory factor level in a joint inflammation part and blood cells and regulating different subtype T cells to be in balance, and has a good anti-rheumatoid arthritis effect. The menthone can be used for preparing the medicine for treating the rheumatoid arthritis, and a new direction is provided for seeking the safe and effective medicine for resisting the rheumatoid arthritis.

Visco-supplement compositions derived from a transcellular fluid, such as human amniotic fluid, human aqueous humor fluid, or human vitreous fluid are described. Also described are methods for treating inflammatory conditions of the musculoskeletal system, such as joint inflammation, and methods of lubricating a joint using the described visco-supplement compositions.

The invention discloses the application of FOXD1 in preparing products for treating and / or preventing animal osteoarthritis. The present invention finds that FOXD1 has the following functions: treating and / or preventing animal osteoarthritis; treating and / or preventing animal anterior cruciate ligament cut-induced osteoarthritis; delaying the aging of mesenchymal stem cells; delaying the replication of mesenchymal stem cells Sexual aging. Experiments have shown that the knockdown of FOXD1 in mesenchymal stem cells in vitro accelerated the aging of mesenchymal stem cells, while the overexpression of FOXD1 delayed the aging of mesenchymal stem cells; in vivo experiments confirmed that FOXD1 gene can reduce the degeneration of articular cartilage and joint Inflammatory response, which has a good therapeutic effect in osteoarthritic diseases. The invention provides a new idea for the development of gene therapy for osteoarthritis, and expands the optional range of clinical gene therapy.

The invention provides the application of tangerine peel essential oil in the preparation of products for preventing or treating arthritis. The research results of the present invention show that the composition of tangerine peel essential oil can alleviate the rat rheumatoid arthritis induced by CFA, and can effectively alleviate the joint tissue damage caused by CFA. The tangerine peel essential oil can inhibit the active expression of tumor necrosis factor TNF-α and COX-2 Thereby inhibiting the lesion degree of arthritis, controlling the joint inflammatory response, thereby relieving the pain caused by arthritis to the greatest extent, and providing a new option for the development of new anti-arthritis drugs.

The invention discloses a traditional Chinese medicine composition for treating gouty arthritis and its preparation method and application. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 5-8 parts by weight of heather leaves, 10-parts by weight of pine knots 15 parts by weight, 20-25 parts by weight of cloth dregs leaves, 20-25 parts by weight of Hydrangea japonica, 6-9 parts by weight of Herba Sinensis, 5-8 parts by weight of Agaricus officinalis root, 5-7 parts by weight of Sorrel, 5 thousand years of health -8 parts by weight. The traditional Chinese medicine composition has the effects of dispelling wind and clearing heat, dehumidifying and relieving pain, regulating qi and dredging collaterals. The results of animal experiments show that the traditional Chinese medicine composition can improve the degree of joint swelling and joint inflammation index of the toes of mice with gouty arthritis, and can also improve the index of immune organs and organs and antioxidant capacity of mice with gouty arthritis, and No side effects. The proposal of the invention provides a new technical means for treating gouty arthritis.

The invention relates to a small molecular compound for treating rheumatoid arthritis, the active ingredient of which is papaya saponin I, and the concentration is 0.1-10 μM. The present invention has been proved by animal experiments that papaya saponin I can reduce joint damage and inflammatory infiltration area, bone mass defect and cartilage defect in mice with collagen-induced rheumatoid arthritis, reduce ankle joint inflammation damage, and can improve rheumatoid joints inflammation symptoms. The invention also discloses the application of the papaya saponin I in the preparation of rheumatoid arthritis medicine or health care product.

The invention discloses a traditional Chinese medicine composition for treating female gouty arthritis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 4-5 parts of aspongopus, 6-7 parts of fenugreek, 6-7 parts of radix echinopsis, 10-15 parts of commelina communis, 0.1-1 part of resina toxicodendri and 4-5 parts of amomum tsao-ko. The traditional Chinese medicine composition has the basic effects of warming kidney and expelling dampness, removing heat and diminishing swelling, and removing blood stasis and resolving stagnation. Experiments prove that the traditional Chinese medicine composition can improve the joint swelling degree, the joint inflammation index and the related inflammatory mediator content of the toe of a female gouty arthritis model mouse, and can also improve the Toll-like receptor-4 protein and gene basic expression level of the toe of the model mouse; the traditional Chinese medicine composition has no influence on visceral organ indexes and body weight of important organs of a model mouse, so that the traditional Chinese medicine composition disclosed by the invention is effective for treating the female gouty arthritis and has no side effect.

The invention generally relates to pharmaceuticals and / or nutraceuticals. More particularly, the invention provides compositions of collagen-based peptides and specific digestive tract microbes useful for supporting or promoting joint, skin and / or bone health, and methods of preparation and use thereof. The invention further provides for the use of compositions of collagen-based peptides as a prebiotic for modulating the gut microbiome.